Modeling resistance to pathway-targeted therapy in ovarian cancer

Deyin Xing, Sandra Orsulic

Research output: Contribution to journalShort survey

Abstract

A detailed understanding of the biochemical pathways that are responsible for cancer initiation and maintenance is critical to designing targeted cancer therapy. Although we have accumulated knowledge about individual molecular changes that underlie cancer development, we are still learning how multiple biochemical pathways cooperate in cancer. This cooperation and cross-talk between redundant biochemical pathways appear to be the main reasons for the failure of therapeutic agents that are designed to interfere with a specific molecular target. In order to simulate the cooperation of several biochemical pathways in cancer development, we have engineered mouse ovarian cancer cell lines and tumors with different combinations of defined genetic alterations. We have used this system to determine the functional contributions of individual pathways that are necessary for cell proliferation and tumor maintenance, as well as to test the molecular mechanisms of tumor resistance to pathway-targeted therapy.

Original languageEnglish (US)
Pages (from-to)1004-1006
Number of pages3
JournalCell Cycle
Volume4
Issue number8
DOIs
StatePublished - Aug 2005
Externally publishedYes

Keywords

  • MEK/ERK
  • Mouse model
  • PD98059
  • PI3K/Akt/mTOR
  • Pathway-targeted therapy
  • Rapamycin
  • Tumor resistance

ASJC Scopus subject areas

  • Molecular Biology
  • Developmental Biology
  • Cell Biology

Fingerprint Dive into the research topics of 'Modeling resistance to pathway-targeted therapy in ovarian cancer'. Together they form a unique fingerprint.

  • Cite this